MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
Globe Newswire•29/07/2026•06:30 ET
0
Whiz Insights
Get started
Create a free account to read the full story.